Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a ...

Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double ...

Vir Biotechnology Inc (VIR) stock saw a decline, ending the day at $12.1 which represents a decrease of $-0.38 or -3.04% from the prior close of $12.48. The stock opened at $12.69 and touched a low of ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Iovance Biotherapeutics (IOVA – Research Report) ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vir Biotechnology (VIR – Research Report), ...

Morgan Stanley (NYSE:MS) analysts have upgraded Vir Biotechnology (NASDAQ:VIR) to an "overweight" rating, shifting from ...

Vir Biotechnology (VIR) stock was upgraded by Morgan Stanley after the company posted trial data for two antitumor agents ...

Following the publication of encouraging results from Phase 2 studies for two investigational cancer treatments, Vir ...

Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and ...

BofA lowered the firm’s price target on Vir Biotechnology (VIR) to $14 from $15 and keeps a Neutral rating on the shares. While political and rate uncertainty continues to be an overhang, the firm ...

Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...